直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
    • AI + Finnegan
    • Appeals, Issues, and Legal Strategy
    • Diligence, Licensing, and Opinions
    • Global IP Enforcement, Litigation, and Trials
    • Patent Office Invalidation Proceedings
    • Prosecution and Portfolio Management
    • Trademark and Brand Management
    • AI, Electronics, and Information Technology
    • Chemicals, Industrials, and Materials
    • Communications
    • Consumer Goods and Services
    • Energy
    • Hospitality, Gaming, and Leisure
    • Life Sciences
    • Transportation and Logistics
  • Experience

Experience

Securing $240 million and a jury verdict of willful infringement for Promptu in patent case against Comcast

Promptu Systems Corporation

US Synthetic secures ITC exclusion order barring polycrystalline diamond compacts (PDCs)

US Synthetic Corporation

Achieving precedent in preserving valuable patents for Lumify®

Eye Therapies, LLC

Finnegan client Maglula delivers crushing blow to Amazon’s arbitration practices over counterfeit products

Maglula, Ltd.

Finnegan secures $180M for CSRC in complex arbitrations

CSRC et al.

Protecting a blockbuster diabetes treatment for AstraZeneca

AstraZeneca AB

Major victories across IP venues for Volkswagen, Audi, Bentley, and Lamborghini

Audi AG; Audi of America, LLC; Automobili Lamborghini America, LLC; Automobili Lamborghini S.p.A.; Bentley Motors Limited; Bentley Motors, Inc; Volkswagen AG; Volkswagen Group of America, Inc.

Finnegan tees up valuable patents for Eisai, leading to major strategic collaboration agreement

Eisai Co., Ltd.

Finnegan helps Intellia Therapeutics acquire Rewrite Therapeutics, Inc. for $45 million

Intellia Therapeutics, Inc.

Recent Experience

Experience

Genzyme Corporation et al. v. Novartis Gene Therapies, Inc. et al. Genzyme Corporation et al. v. Novartis Gene Therapies, Inc. et al.

1:21-cv-01736, 1:23-cv-00554, D. Del., Judge Andrews

Experience

CMC Materials, LLC v. Dupont de Nemours, Inc. et al. CMC Materials, LLC v. Dupont de Nemours, Inc. et al.

1:20-cv-00738, D. Del., Judge Hall

Dupont de Nemours, Inc. et al.

Experience

American Regent, Inc. v. Pharmacosmos Therapeutics Inc. et al. American Regent, Inc. v. Pharmacosmos Therapeutics Inc. et al.

PGR2020-00009, PTAB, Judges Tornquist, Franklin, Wisz
3:20-cv-01350, D.N.J., Judges Goodman, Martinotti, Quraishi

Experience

Vifor (International) AG and American Regent, Inc. v. Mylan Labs. Ltd. et al. Vifor (International) AG and American Regent, Inc. v. Mylan Labs. Ltd. et al.

3:19-cv-13955, 3:19-cv-16305, D.N.J., Judges Wolfson, Arpert

Experience

Eli Lilly and Company v. Teva Pharmaceuticals International Eli Lilly and Company v. Teva Pharmaceuticals International

IPR2018-01422; -01423; -01424; -01425; -01426; -01427; -01710, -01711, -01712, PTAB

Experience

Teva Pharmaceuticals International GmbH v. Eli Lilly and Company Teva Pharmaceuticals International GmbH v. Eli Lilly and Company

1:18-cv-12029, D. Mass., Judge Burroughs

Experience

Eli Lilly and Company v. Actavis Labs. UT Inc. Eli Lilly and Company v. Actavis Labs. UT Inc.

1:16-cv-01119, E.D. Va., Judges Nachmanoff, Trenga

Experience

Duchesnay, Inc. v. Actavis Laboratories Inc. and Mylan Pharmaceuticals, Inc. Duchesnay, Inc. v. Actavis Laboratories Inc. and Mylan Pharmaceuticals, Inc.

1:14-cv-00912, D. Del., Judges Robinson, Fallon

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP